60301-20-4

Usage

Uses

Used in Pharmaceutical Research:
1-methyl-1H-indazol-3-amine is used as a building block for the synthesis of pharmaceutical compounds due to its unique chemical structure and potential to form biologically active molecules.
Used in Medicinal Chemistry:
1-methyl-1H-indazol-3-amine is utilized as a key intermediate in the development of new drugs, contributing to the advancement of medicinal chemistry by providing a versatile scaffold for the design of novel therapeutic agents.
Used in Drug Discovery:
1-methyl-1H-indazol-3-amine is employed as a starting material in drug discovery processes, where its properties are explored and optimized to identify new lead compounds with potential therapeutic applications.
Used in Organic Synthesis:
1-methyl-1H-indazol-3-amine is used as a reagent in organic synthesis, enabling the formation of a variety of complex organic molecules that can be further utilized in pharmaceutical and chemical research.

InChI:InChI=1/C8H9N3/c1-11-7-5-3-2-4-6(7)8(9)10-11/h2-5H,1H3,(H2,9,10)

Upstream product

• 113385-39-0 2-(1-Methyl-1H-indazol-3-yl)-isoindole-1,3-dione 
• 874-05-5 3-aminoindazole 
• 360575-28-6 2-bromo-6-fluorobenzaldehyde 
• 13436-48-1 1-methyl-1H-indazole 
• 394-47-8 2-fluorobenzonitrile 
• 365427-30-1 4-bromo-1-methyl-1H-indazole 
• 1073-06-9 3-fluorobromobenzene 
• 60-34-4 methylhydrazine 
• 82575-23-3 2-(1H-indazol-3-yl)isoindoline-1,3-dione 

Downstream Products

• 13436-48-1 1-methyl-1H-indazole 

Relevant academic research and scientific papers

Site-selective arene C-H amination via photoredox catalysis

Over the past several decades, organometallic cross-coupling chemistry has developed into one of the most reliable approaches to assemble complex aromatic compounds from preoxidized starting materials. More recently, transition metal-catalyzed carbon-hydrogen activation has circumvented the need for preoxidized starting materials, but this approach is limited by a lack of practical amination protocols. Here, we present a blueprint for aromatic carbon-hydrogen functionalization via photoredox catalysis and describe the utility of this strategy for arene amination. An organic photoredox-based catalyst system, consisting of an acridinium photooxidant and a nitroxyl radical, promotes site-selective amination of a variety of simple and complex aromatics with heteroaromatic azoles of interest in pharmaceutical research. We also describe the atom-economical use of ammonia to form anilines, without the need for prefunctionalization of the aromatic component.

A method for the regioselective synthesis of 1-alkyl-1H-indazoles

A method for the regioselective synthesis of 3-unsubstituted 1-alkyl-1H-indazoles, starting with 2-halobenzonitriles and N-alkylhydrazines, is described. The two-step reaction pathway proceeds through the intermediacy of 1-alkyl-3-amino-1H-indazoles follo

TRPV1 Antagonists

Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, solvates, or combinations thereof, wherein X1, X2, X3, X4, J, K, L, X5, X6, Rb, G2, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

A general, one-step synthesis of substituted indazoles using a flow reactor

Flow chemistry is a rapidly emerging technology within the pharmaceutical industry, both within medicinal and development chemistry groups. The advantages of flow chemistry, increased safety, improved reproducibility, enhanced scalability, are readily apparent, and we aimed to exploit this technology in order to provide small amounts of pharmaceutically interesting fragments via a safe and scalable route, which would enable the rapid synthesis of multigram quantities on demand. Here we report a general and versatile route which utilises flow chemistry to deliver a range of known and novel indazoles, including 3-amino and 3-hydroxy analogues.

BICYCLIC PYRIMIDINONES AND USES THEREOF

The present invention provides a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. A pharmaceutical composition or medicament comprising a compoundof Formula I is also provided.